December 15, 2021 Press release - Regulatory Targovax awarded NOK 9.8m research grant by the Research Council of Norway towards the TG mutant RAS program
November 30, 2021 Press release - Regulatory Targovax ASA – Commencement of the subscription period for the rights issue
November 25, 2021 Press release - Regulatory Targovax ASA – Rights issue approved by the extraordinary general meeting
November 24, 2021 Press release - Regulatory Targovax ASA – Terms of the fully underwritten rights issue
November 4, 2021 Press release - Regulatory Targovax ASA – Key information relating to the preferential rights issue
August 18, 2021 Press release - Regulatory Targovax ASA: second quarter and first half year 2021 results
August 9, 2021 Press release - Regulatory Targovax ASA: Invitation to presentation of Targovax’s second quarter and first half 2021 results, Wednesday 18 August
July 1, 2021 Press release - Regulatory Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer
June 28, 2021 Press release - Regulatory Targovax to present at the 4th Annual Next Gen Immuno-Oncology Virtual Congress-US Edition
June 22, 2021 Press release - Regulatory Targovax receives Fast Track designation for ONCOS-102 in melanoma
June 17, 2021 Press release - Regulatory Targovax announces completed enrollment in the phase 1/2 trial with ONCOS-102 in combination with durvalumab in patients with advanced colorectal cancer with peritoneal malignancies
June 14, 2021 Press release - Regulatory Targovax releases presentations of ONCOS-102 mesothelioma 24-month data
March 4, 2021 Press release - Regulatory Targovax ASA: Registration of share capital increase following exercise of options
March 1, 2021 Press release - Regulatory Targovax ASA: Exercise of options under LTI program and resolution to increase the share capital
